Biocen

Biocen is a leading biopharmaceutical company focused on providing affordable and accessible healthcare solutions globally. With a strong commitment to making quality medicines available to all, Biocen aims to reach a billion patients worldwide with its innovative and inclusive healthcare offerings. The company's core products include generics, biosimilars, research services, and novel biologics, addressing unmet medical needs across the globe. Biocen's expansive portfolio spans insulins, monoclonal antibodies, and recombinant proteins, with a commercial footprint in over 100 countries, catering to both advanced and emerging markets.

Known for its rich legacy of scientific advancement, Biocen has been at the forefront of healthcare innovation, with a track record of notable achievements such as being the first company globally to receive U.S. FDA approval for various biologics. The company's commitment to health equity is reflected in its Environmental, Social, and Governance (ESG) practices, focusing on patient equity, people equity, environment equity, stakeholder equity, and social equity. Biocen's leadership approach is driven by a humanitarian purpose, emphasizing the importance of making healthcare affordable and accessible, even to the most underserved populations.

With a strategic focus on transforming healthcare and improving patient outcomes, Biocen continues to drive innovation in biologics, reduce the global healthcare burden, and increase treatment options for a diverse customer base. The company's dedication to addressing the world's developmental challenges underscores its mission-driven approach, positioning Biocen as a key player in the biopharmaceutical industry. As Biocen looks towards the future, its commitment to advancing health equity, globally, remains at the forefront of its strategic direction, ensuring a sustainable impact on the healthcare landscape.